Joseph Yang

Joseph Yang

Auto-generated profile, based on publicly available information

Joseph Yang

Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Rheumatology
Verified
Journal Article
Open access
JYJoseph Yang
Joseph Yang
MHMichael A Head
Michael A Head
KSKevin D Schott
Kevin D Schott
HTHiangkiat Tan
Hiangkiat Tan
RDRachel Djaraher
Rachel Djaraher
EBElana J. Bernstein
Elana J. Bernstein
Objectives: We aimed to describe the demographics, clinical characteristics and care patterns of patients with systemic autoimmune rheumatic diseases (SARD) prior to their interstitial lung disease (ILD) diagnosis. Methods: We conducted a retrospective cohort study using claims data from Healthcare Integrated Research Database (2006–2023). Adults diagnosed with SARD-ILD were identified, with the earliest ILD diagnosis date designated as the index date. A minimum of 36 months of continuous enrolment before the index date was required. All measures were analysed descriptively. For a subset of patients with respiratory symptoms before ILD diagnosis, the association between type of specialist encounter and time from symptom onset to SARD-ILD diagnosis was assessed using a Cox proportional hazards model. Results: The study included 2526 patients with SARD-ILD. Mean age was 62.6 years and 75.4% were female. Before ILD diagnosis, 61.8% of patients had at least one all-cause hospitalization. Diagnostic tests including chest CT, high-resolution CT, and pulmonary function tests (PFT) were used in 80.1%, 59.0% and 60.3% of patients, respectively. Among the subgroup, patients who saw a pulmonologist within 90 days of initial respiratory symptom onset were 18% more likely to be diagnosed with ILD compared with those who did not (hazard ratio: 1.18, 95% CI: 1.03, 1.35; P = 0.017). Conclusion: The study highlights the complex diagnostic journey of patients with SARD-ILD. Findings suggest a multidisciplinary approach involving pulmonologists and rheumatologists could enable timely ILD diagnosis and should be considered for more effective diagnosis and management of SARD-ILD.

7 April 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
JYJoseph Yang
Joseph Yang
KSKaty Sadowski
Katy Sadowski
AKAkshay Kharat
Akshay Kharat
ACAnn Chauffe
Ann Chauffe
TKTejaswini Kulkarni
Tejaswini Kulkarni
Objective Patients with systemic autoimmune rheumatic disease (SARD) are at high risk of developing interstitial lung disease (ILD). We sought to gain insight into the pharmacological and non-pharmacological treatments being used by patients with SARD-associated ILD (SARD-ILD) following ILD progression. Design This was a retrospective, observational cohort study. Setting Optum Clinformatics Data Mart administrative medical and pharmacy claims database in the USA. Participants Patients with SARD-ILD who had an incident ILD diagnosis and progression between January 2018 and March 2023. Primary and secondary outcome measures Treatment patterns and healthcare services utiliation were descriptively summarised for baseline and follow-up periods. Results We identified 6431 patients with SARD-ILD and evidence of ILD progression (mean age, 71.2 years; 75.3% female; 68.9% white). The mean (SD) time between the initial SARD-ILD diagnosis and the onset of ILD progression (index date) was 104 (201) days. On average, patients were followed for 936 (467) days. Oral corticosteroids were the most common treatment post-progression (69.5%), followed by non-biologic disease-modifying antirheumatic drugs (non-biologic DMARDs) (41.6%), biologic DMARDs (15.5%) and immunomodulators (15.4%). Antifibrotics were received by 3.5% of patients. Supplemental oxygen was the most frequent non-pharmacological treatment (48.9%). For the baseline period, 53.0% and 42.1% of patients used inpatient and emergency department services, respectively. During the follow-up, 69.7% and 62.8%, respectively, used these services. Conclusion The high use of corticosteroids and limited use of DMARDs and antifibrotics post-progression in this descriptive study implies a significant gap between current practice and optimal management of patients with SARD-ILD.